TriSalus Life Sciences, Inc. TLSI Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$27.31M-0.4% | -$39.23M-30.6% | -$39.58M+28.8% | -$31.17M+42.9% | -$27.21M+57.6% | ||
| $589K-20.5% | $626K-15.9% | $693K-7.0% | $712K-1.0% | $741K+9.8% | ||
| $9.98M+67.1% | $9.13M+67.8% | $8.63M+81.9% | $6.59M+82.0% | $5.98M+148% | ||
| $1.11M+31.1% | $1.05M+71.4% | $945K+118% | $837K+213% | $847K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.11M-57.3% | $1.36M-48.9% | ||
| -$384K-131% | -$971K-165% | -$724K-131% | $363K-81.1% | $1.25M— | ||
| $556K+120% | $2.02M+143% | $1.33M+83.7% | -$2.21M-17.2% | -$2.76M-210% | ||
| —— | —— | —— | —— | —— | ||
| $287K-20.5% | $429K+62.5% | $438K+43.6% | $322K-9.0% | $361K+35.2% | ||
| -$109K+56.2% | -$134K+51.8% | -$147K+53.6% | -$189K+62.9% | -$249K+15.3% | ||
| -$5.48M+64.0% | $2.74M+123% | -$2.4M— | -$2.24M— | -$15.23M— | ||
| -$19.99M+42.0% | -$18.01M+55.9% | -$21.24M+52.1% | -$28.37M+48.5% | -$34.48M+32.3% | ||
| —— | —— | —— | —— | $1.03M+59.7% | ||
| —— | —— | —— | —— | $40K— | ||
| —— | —— | —— | —— | -$993K+37.2% | ||
| —— | —— | —— | $30.57M+353% | $11.96M+281% | ||
| $19K-85.7% | $81K-3.6% | $97K+11.5% | $113K+29.9% | $133K+52.9% | ||
| —— | —— | —— | —— | $3.12M— | ||
| $63.46M+42.6% | $30.76M-18.9% | $33.48M-4.3% | $39.22M-43.5% | $44.5M-10.7% | ||
| —— | —— | —— | $10.01M— | $9.03M— | ||
| $4.13M+67.6% | $3.7M+110% | $2.53M+43.5% | $2.86M+522% | $2.46M+14,827% | ||
| —— | —— | —— | $30K+173% | $19K+81.0% | ||
| —— | —— | —— | —— | $179.25K— | ||
| $1.11M+31.1% | $1.05M+71.4% | $945K+118% | $837K+213% | $847K— | ||
| -$5.48M+64.0% | $2.74M+123% | -$2.4M— | -$2.24M— | -$15.23M— | ||
| $638K— | -$4.1M— | -$4.68M— | —— | —— | ||
| -$109K+56.2% | -$134K+51.8% | -$147K+53.6% | -$189K+62.9% | -$249K+15.3% | ||
| —— | —— | —— | —— | —— | ||
| $287K-20.5% | $429K+62.5% | $438K+43.6% | $322K-9.0% | $361K+35.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $40K— | ||
| $19K-85.7% | $81K-3.6% | $97K+11.5% | $113K+29.9% | $133K+52.9% | ||
| —— | —— | —— | —— | $3.12M— | ||
| —— | $404K-6.7% | $411.25K— | $418.5K— | $425.75K— | ||
| —— | —— | —— | —— | $87K+511% | ||
| —— | $0-100% | $2.98M-66.7% | $5.96M0.0% | $8.94M+200% | ||
| —— | —— | —— | —— | $85K— | ||
| —— | —— | —— | —— | —— | ||
| -$109K+56.2% | -$134K+51.8% | -$147K+53.6% | -$189K+62.9% | -$249K+15.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $30K+173% | $19K+81.0% | ||
| -$20.3M+42.8% | -$18.93M+54.0% | -$22.16M+50.7% | -$29.25M+47.6% | -$35.51M+31.2% | ||
| -$20.3M+42.8% | -$18.93M+54.0% | -$22.16M+50.7% | -$29.25M+47.6% | -$35.51M+31.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does TriSalus Life Sciences, Inc. generate?
- TriSalus Life Sciences, Inc. (TLSI) generated -$20.0M in operating cash flow over the trailing twelve months.
- What is TriSalus Life Sciences, Inc.'s free cash flow?
- After $1.2M of capital expenditures, TriSalus Life Sciences, Inc.'s free cash flow was -$20.3M over the trailing twelve months, up 42.8% year over year.
- Where does TriSalus Life Sciences, Inc.'s cash flow data come from?
- Every line is extracted from TriSalus Life Sciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
